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Diabetes is a serious endocrine and metabolic disease that affects many organs in 
the body. This disorder is characterized by hyperglycemia, and increased plasma levels 
of lipids and amino acids. There are many in vivo studies evaluating the interdependence 
of hyperglycemia and hypertriglyceridemia, however the relationship of these two factors 
in in vitro models is poorly understood.
Studies to evaluate the effects of hypertriglyceridemia on hyperglycemia in an in 
vitro model using two different cell types (sheep aortic endothelial cells and sheep 
arterial smooth muscle cells) were performed in the absence and presence of triglycerides 
(45 mg/dl, 200 mg/dl). The disappearance of glucose from medium containing two 
different initial glucose concentrations (70 mg/dl, 300 mg/dl) was measured in the 
absence or presence of insulin.
High lipid levels caused abnormalities in insulin-dependent glucose clearance in 
both cell types, but the responses of the cells were distinctive. Conditions mimicking 
hyperglycemia and hyperlipidemia induced a response from endothelial cells that 
resembled insulin resistance. These conditions also caused a loss of adherence by smooth 
muscle cells. The patterns of glucose clearance in the presence of 45 mg/dl triglycerides 
were very similar for both cell types, except in hyperglycemic conditions The 
physiologic levels of lipids enhanced glucose clearance in both cell types.
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1.0 INTRODUCTION
Diabetes is a serious endocrine and metabolic disease that affects many organs in 
the body. The pathology includes a variety of clinical symptoms including premature 
mortality, blindness and renal disease. Diabetes is characterized by hyperglycemia as 
well as by increased plasma levels of lipids and amino acids. Most patients with diabetes 
have a predisposition to atherosclerosis and neuropathic disorders (88).
The number of diabetic patients in the U.S.A. increased greatly between 1980 and 
1994. In 1994 Diabetes Mellitus was the 7^ leading cause of death with 8 million new 
cases diagnosed (17). The 1997 Surveillance Report from Centers for Disease Control 
and Prevention indicated that the incidence of Type II Diabetes Mellitus was higher 
among African Americans, Asians and Native Americans when compared with whites 
(17).
There are two major types of Diabetes Mellitus; Insulin Dependent Diabetes 
Mellitus, or type I (IDDM) and Non-insulin Dependent Diabetes Mellitus also called type 
II (NIDDM). The division into the two major types of Diabetes Mellitus was first 
observed in the 1930s. Himsworth performed experimentations in which he observed 
blood glucose responses after the administration of insulin (7). Upon these studies, he 
suggested that there were two different types of Diabetes Mellitus. Patients in one group 
were insulin sensitive (Type I Diabetes Mellitus), and in the other group insulin 
insensitive (Type II Diabetes Mellitus).
Type I Diabetes Mellitus shows rapid onset usually in young individuals, but may 
occur at any age. Anti-islet-cell antibodies are present at the onset, leading to injury and
destruction of pancreatic cells. Endogenous insulin is usually minimal or absent. This 
type of diabetes presents commonly with ketoacidosis (88).
Type II shows insidious onset and is frequently seen in nonnal or obese 
individuals 35 years and older, but it may occur at any age (reviewed in ref. 88). Anti­
islet-cell antibodies are not observed in this type of diabetes. There may be adequate 
amounts of insulin with delayed secretion, inadequate release of insulin, or adequate 
insulin in the presence of insulin resistance. Ketosis is seen mainly during infection or 
stress. When insulin is produced, but the body is refractory to its action (insulin 
insensitivity), several congenital syndromes may be present including acanthosis 
nigricans, hyperlipidemia, growth abnormalities, ovarian hyperandrogenism, ovarian 
cysts, elevated androgen levels, and neonatal leprechaunism. Many patients who suffer 
from these congenital syndromes do not have elevated plasma glucose levels, but usually 
show mildly impaired glucose tolerance. Glucose tolerance is determined by a glucose 
tolerance test, which measures blood glucose levels at intervals after ingestion of a 
known amount of glucose. The test result is considered normal if fasting plasma glucose 
is less than 115 mg/dl, and plasma glucose following 2hrs post ingestion is less than 
140 mg/dl. The glucose intolerance is a pathological state in which fasting plasma 
glucose is less than 140 mg/dl and the 30, 60 or 90 min plasma concentration following a 
glucose tolerance test exceeds 200 mg/dl. Glucose intolerance is often seen in Type 11 
Diabetes Mellitus. Hyperglycemia, or excess sugar in the bloodstream in Diabetes 
Mellitus leads to glycosylation of proteins, dehydration causing hyperosmolality (more 
than 325 mOsm/1), and end-organ damage (retinopathy, nephropathy). High plasma 
glucose causes osmotic shifts, and intracellular formation of other sugars (sorbitol) which
result in swelling of the lens of the eye, blurred vision, and formation of cataracts, as well 
as nerve damage. Proteins such as hemoglobin, albumin and collagen become 
glycosylated to a greater extent. This may contribute to the long-term tissue damage in 
the retina, kidneys, nerves, and cardiovascular system (7,27). In order to prevent damage 
from hyperglycemia, glucose homeostasis is very important and is accomplished through 
insulin-stimulated glucose uptake. Factors other than hyperglycemia that are relevant to 
Type II Diabetes Mellitus are hyperinsulinemia and hyperlipidemia (69,84,92,101).
Insulin resistance and abnormal triglyceride levels (12,96) are often found in 
patients with impaired glucose tolerance and Type II Diabetes (77,78,87). In addition, 
increased plasma insulin levels are found in patients with elevated plasma triglyceride 
levels (39,75). In the presence of high insulin levels, the liver increases production of 
triglycerides and very low density lipoproteins (VLDL) (93) leading to obesity and 
enhanced risk of atherosclerosis.
1.1 Insulin
Insulin is a peptide hormone of molecular weight 6,000 produced by the cleavage 
of proinsulin before being secreted by beta pancreatic cells. It consists of two amino acid 
chains, A and B, containing 21 and 30 amino acids respectively, which are linked by 
disulfide bonds (7).
The hormone, insulin, is secreted in response to changed levels of glucose, amino 
acids, or gut hormones. This hormone stimulates the uptake of glucose and, at the same 
time, inhibits mobilization of endogenous substrates, such as glycogen. When glucose 
decreases, insulin secretion will cease and mobilization of endogenously stored
carbohydrates will occur. There is a sigmoidal relationship between glucose and insulin 
(7)(Fig. 1). Normal fasting plasma glucose levels are 80-115 mg/dl. Insulin is not 
secreted when levels are below 50 mg/dl. On the other hand, the maximum insulin 
response is seen when glucose levels are about 300 mg/dl (7). Insulin is released when 
plasma glucose increases 10 mg/dl or more, but soon returns to baseline. If plasma 
glucose levels continue to increase, insulin release will be in its second phase, 
characterized by a slower rise of insulin and a plateau. In normal individuals the second 
phase can be seen for several hours (7).
1.2 Insulin regulation
Stimulatoiy factors for insulin secretion other than glucose include free fatty 
acids, amino acids (arginine, lysine, leucine and alanine), gastrin, cholecystokinin, 
secretin, intestinal peptide, and gastrin-releasing peptide. When glucose is given orally, 
the insulin response will be greater than if glucose is given intravenously. This is due to 
release of these gastrointestinal hormones (7). Sympathetic nerve activation, infection, 
surgery and stress inhibit insulin secretion through an alpha-adrenergic mechanism (88).
There are several glucose regulatory hormones that counteract the action of 
insulin (Reviewed in Ref. 7). These include glucagon, epinephrine, cortisol and growth 
hormone. Glucagon increases hepatic gluconeogenesis, and decreases hepatic storage of 
carbohydrates. Epinephrine, through its beta-adrenergic action, is known to cause 
glucose intolerance. It stimulates glycogenolysis, gluconeogenesis and proteolysis. 
Increased lipolysis leads to elevated free fatty acids. Ketogenesis is stimulated, whereas 
peripheral ketoacid use is inhibited. Other counter regulatory hormones include cortisol.
maintaining all the important enzymes in gluconeogenesis, and growth hormone, 
responsible for increased usage of free fatty acids, and causing insulin resistance as well.
The understanding of insulin regulation by honuones and other factors is an 
important concept. The complexity of the regulatory network requires that in vitro 
studies be carefully planned. Part of the goal of this project was to develop an in vitro 
model of glucose clearance using only insulin. The complex effects of other hormones 
on glucose regulation were eliminated to simplify the situation. However, the effects of 
other hormones are important and need to be evaluated in the future.
1.3 Insulin receptors
Insulin receptors are found on many cells and their number varies with different 
types of cells (reviewed in ref. 88). Insulin receptors consist of two a  and p subunits, 
which are linked through disulfide bonds. Alpha subunits are extracellular and serve as 
the binding site for insulin, while the P subunits form transmembrane segments 
associated with integral protein tyrosine kinase activity (127). Insulin binding to the 
a  subunit of the receptor causes conformational changes responsible for receptor 
aggregation and partial activation of the tyrosine kinase (32,98,125,126). Upon partial 
activation, the tyrosine kinase autophosphorylates by a trans-mechanism, stimulating 
phosphorylation of the p subunit at three key tyrosines (amino acids 1146, 1150 and 
1151) (7) causing fully active tyrosine kinase activity. The activated tyrosine kinase, in 
turn, phosphorylates different intracellular proteins that initiate the signal transduction 
cascade. The mechanism of transmembrane signal transmission is not fully known. The 
hormone receptor complex is then internalized by endocytosis leading to hormone
degradation and receptor storage and recycling back to the plasma membrane. Hereditaiy 
defects in insulin receptors can cause diminished or decreased tyrosine kinase activity 
resulting in diabetic symptoms (7). Activation of insulin receptors and initiation of the 
signal transduction cascade results in glucose transport which is the rate-limiting step for 
the utilization of glucose (31,69,129).
1.4 Glucose transport
Glucose is transported across the plasma membrane via gradient driven facilitated 
diffusion mediated by glucose transport proteins. When the gradient reaches zero, 
facilitated diffusion of glucose or other substances stops (18).
There are six closely related genes encoding transporter proteins (GLUT 1 -6) and 
one pseudogene (GLUT 7) shown in Table 1 (5,15,42,65). All six glucose transporters 
have sequence similarity in 12 hydrophobic transmembrane regions (36,57,68).
Mutations in these transmembrane regions of genes encoding for glucose transport 
function can have negative effects on binding or transport. For example, mutations in N- 
linked glycosylation sites diminish the function of the GLUT 1 glucose transporter (2- 
4,30,36,48,57,68,106).
Each isoform of glucose transporter has different kinetic properties and kinetic 
studies are difficult, because of the mixture of different isoforms within a given tissue. 
The Km differs with respect to different cell types (44). GLUT 4 transports glucose faster 
and it has a higher affinity for glucose than GLUT 1. The Km for the GLUT 4 was found 
to be close to normal physiologic levels for glucose (2 -  lOmM) and was lower than the 
Km for GLUT 1 (22). The Km for GLUT 3 is 1.4+/- 0.06mM (89). The GLUT 5 and
GLUT 2 isoforms play a major role in fructose transport. GLUT 1,2, and 3 are mannose 
transporters and xylose is also transported by isoform GLUT 3 (14,44,94).
The GLUT 2 isoform is found mainly in the plasma membrane of hepatocytes 
and in pancreatic P-cells, where it senses glucose concentrations resulting in alterations in 
insulin secretion. GLUT 7 is found in microsomes of hepatocytes involved in glucose 
export to the cytosol following gluconeogenesis (15,119,123,124).
GLUT 1 and GLUT 3, with intermediate Km constants, are mainly found in the 
blood brain barrier and neuronal tissue, providing a constant flow of glucose 
(43,81,83,104). GLUT 5 was also present, but the reason for its presence is not known 
(86,105).
The most important transporters for the laboratory experiments using muscle cells 
and endothelial cells, are the GLUT 4 and GLUT 1 isoforms, the main transporters in 
muscle and endothelial cells respectively (19,54,131,116) (see Table 1). When there is 
no insulin present, GLUT 4 is found intracellularly in myocytes and adipocytes. In the 
presence of insulin, there is translocation of GLUT 4 to the plasma membrane, which 
leads to rapid removal of glucose from the blood (41,49,70). This translocation is not 
observed for GLUT 1 and GLUT 5 isoforms (13,105).
It has been suggested that alterations in the number of GLUT4 transporters may 
be responsible for insulin resistance (2,45,64,66). Plasma membrane levels of GLUT 4 
were found to be lower in type II diabetics accompanied by increased cAMP, and 
decreased GLUT 4 mRNA synthesis (63,113).
Translocation of glucose transporters from an intracellular pool to the plasma 
membrane (25,79) was studied using phorbol esters (55), which are known to stimulate
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protein kinase C (37,121,122). It was found that phorbols also enhance the translocation 
of glucose transporters. Administration of protein kinase C inhibitors decreased glucose 
transporter translocation. This suggested that protein kinase C played a role in the 
translocation of glucose transporters (37,55,58,91,121,130). The exact sequence of the 
glucose transporter translocation and effects of protein kinase C are not known 
(79,90,102). Hormone signaling, exercise, and contraction can cause GLUT 4 
translocation in muscle; however, the exact place where GLUT 4 is translocated in 
muscle cells is unknown (10,54,131). Circulating fatty acids are thought to influence 
translocation of GLUT 4 in adipocytes (102).
Previous research indicated that there was a delay between the translocation of 
GLUT 4 glucose transporter and the actual glucose transport, suggesting that transport 
was a regulated process (19,128). First the transporter had to be partially inserted into the 
cellular plasma membrane and then activation occurred, resulting in glucose transport. 
The activation process allowed the proper conformational change needed for glucose 
binding (41,94).
Once the correct position of the transporter is accomplished, its intrinsic activity 
can be modulated. The mechanism of this modulation is not known. The intrinsic 
activity can be influenced by a variety of substances such as: phlorizin, adenosine, 
isoproterenol, epinephrine and agents acting through G-protein coupled receptors 
(38,62,67,76). Glucose transporter recycling is also a regulated process that is presently 
not very well understood (107).
Relationship between plasma 
glucose and insulin secretion
g. 10001 80
1 60c
3(/) 40c
1 20
nK 0
100 200 300
Plasma glucose (mg/dl)
400
Fig. 1 In vivo relationship between plasma glucose and insulin secretion is 
sigmoidal Diabetes 23:763, 1974 (7).
1 0
Isoform Tissue distribution Comments
GLUT 1 Erythrocytes, blood -  brain 
barrier, placenta, kidney, 
perineuria] sheath of 
muscle, lower levels in 
adipocytes
Largely a basal transporter; 
important in many tissues. 
Asymétrie glucose transport 
kinetics
GLUT 2 Liver, small intestine, 
kidney, pancreatic p - cells
High Km transporter. 
Therefore at physiological 
glucose levels will transport 
glucose at rate proportional 
to concentration of glucose
GLUT 3 Neurons, placenta. Lower 
levels in liver heart, small 
intestine
Basal glucose transporter 
found in tissues with 
constant need for glucose as 
a metabolic fuel
GLUT 4 Skeletal muscle, heart, 
brown and white fat
Low Km, sequestered 
intracellularly in the 
absence of insulin. 
Translocated from 
intracellular pool to plasma 
membrane in response to 
insulin
GLUT 5 Small intestine. Lower 
levels in sperm, muscle, fat, 
brain and kidney
Basal transporter. Has a 
high affinity for fructose
GLUT 6 Pseudogene — not translated 
into protein
GLUT 7 Liver microsomes Functions in intracellular 
transport of glucose
Table 1. Glucose transporters isoforms, their tissue distribution and characteristics (88).
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A great deal of research has been done to explore the roles and regulation of 
insulin, insulin receptors, and glucose transporters in maintaining plasma glucose levels 
(2,5,10,25,45,70). However, it has become clear that many other factors affect glucose 
homeostasis. Hyperlipidemia, often seen with Type II diabetes, is receiving considerable 
attention because of its possible role in the development of cardiovascular diseases 
associated with diabetes (9, 75, 88).
1.5 Hvnerlipidemia
Blood with increased amounts of lipids (hyperlipidemia) is an important symptom 
of Diabetes Mellitus. Hyperlipidemia may result from a defect in the gene controlling 
low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) receptors, or an 
inability to metabolize LDL and VLDL (88) or from enhanced rates of adipose tissue 
lipolysis.
A number of in vivo and in vitro studies have been performed to investigate the 
role of hyperlipidemia and insulin resistance in Diabetes Mellitus. Plasma of patients 
with Type II Diabetes Mellitus contained high levels of triglycerides, and decreased 
levels of high- density lipoprotein (HDL) and apolipoprotein A (75). Type II patients 
accumulated intermediate density lipoproteins and small dense LDL in the presence of 
hypertriglyceridemia, which showed impaired binding to LDL receptors (9, 53). High 
plasma triglyceride concentrations have also been associated with hyperinsulinemia, 
increased plasma levels of VLDL, and abnormal glucose tolerance (16).
Hyperlipidemia may also occur from excess free fatty acids accompanied by 
stimulation of gluconeogenesis, insulin resistance, glucose intolerance, or increased
12
lipolysis and may interfere with normal cellular metabolic function and signal 
transduction (85,88). Hypertriglyceridemia is associated with elevated glucose levels, 
and impaired cellular expression of the insulin gene (120). Elevated lipids also decrease 
the number of cellular glucose transporters (45,63).
1.6 Muscle cells
There are three types of muscle cells; skeletal muscle responsible for skeletal 
motion, cardiac muscle cells found in heart and large vessels, and smooth muscle cells 
present in blood vessel walls and elastic organs such as the uterus and bladder (117). 
Muscle is one of the most important organs in maintaining glucose homeostasis.
Glucose uptake by muscle cells is regulated by insulin (88), with glucose transport as the 
rate-limiting step (31,70,129).
Although insulin normally stimulates glucose transport in muscle cells, in insulin 
resistance glucose levels remain high despite the presence of insulin. In this case, more 
and more insulin is secreted, leading to hyperinsulinemia. In the presence of high levels 
of insulin, studies have shown that glucose transport by muscle cells was depressed 
(24,59) and showed significant lipid uptake (114) with increased glucose conversion to 
lipids (84). It was found that lipoprotein lipase activity in muscle cells was inversely 
correlated with plasma insulin concentration (23). The rate of glucose utilization, insulin 
sensitivity, and maximum insulin responsiveness in muscle diminished with congenital 
generalized lipodystrophy (120), or aging (40), and was increased by the influence of 
exercise due to increased extraction and delivery of glucose to the muscle cells (50).
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1.7 Endothelial cells
Endothelial cells play important roles in the formation of a smooth 
antithrombogenic surface in blood vessels, coagulation, thrombolysis, antigen 
presentation (28,95), and passage of nutrients, solutes, and hormones from blood to the 
extravascular space (21). Since dysfunction of vascular endothelium is associated with 
Diabetes Mellitus (20), several studies exploring lipoprotein degradation and insulin 
stimulated glucose uptake in endothelial cells have been performed.
Human endothelial cells grown in cell culture in the presence of hyperglycemic 
conditions showed fonnation of glycosylated LDL and inhibition of its degradation as 
compared to normal (nonglycosylated) LDL. The decreased recognition of these LDL 
molecules by the endothelial lining of blood vessels may play a role in abnonnal tissue 
physiology (80). High concentrations of glucose added to the cell culture media reduced 
the number of endothelial cells by 78% compared to controls and the presence of insulin 
decreased glucose uptake of endothelial cells, possibly due to changes in osmolality (1). 
Decreased glucose uptake was also observed in diabetic endothelial cells (101).
1.8 Significance
Glucose uptake by cells has been extensively studied. Mechanisms of glucose 
transport, insulin signaling, and some aspects of signal transduction of insulin are known. 
However, a direct comparison of glucose clearance by different cells using an in vitro 
assay system under physiological and pathological conditions has not yet been 
performed. Such a study could provide important clues to our understanding of 
pathologies associated with Type II Diabetes Mellitus, such as atherosclerosis and insulin
14
resistance. Therefore, it was important to design an in vitro system which could 
accurately measure changes in glucose clearance in the presence of lipids.
In order to compare the action of insulin on different cell types in vitro, during 
hyperglycemia and hyperlipidemia, it was important to normalize the assay system in 
terms of the number of cells and culture conditions. The normalization of the assay 
system must also be considered when parameters are changed by increasing amounts of 
lipids to assure that only true functional differences between the different cells studied 
will be observed.
1.9 Hypothesis
When looking from a historic point of view, a basal level of plasma glucose was 
probably necessary for providing energy to cells in performing strenuous life sustaining 
work. On the other hand, the lifestyle of modem man has completely changed. Food is 
readily available, and less exercise is common. Thus, in general, less energy is required 
for daily activities, and very often more energy enters the system (body) than is 
expended. The result is an accumulation of metabolic fuels, which are stored mostly as 
fat. Excess stored body fat leads to obesity associated with insulin resistance (108). 
Because insulin resistance is associated with altered glucose clearance and 
hyperlipidemia, it is essential to explore the effects of hyperlipidemia on insulin- 
dependent glucose clearance. Endothelial cells can be likely affected by both 
hyperglycemia and hyperlipidemia since they are in direct contact with the plasma (1,20). 
In addition, alteration of arterial smooth muscle cells has been shown to be associated 
with atherosclerosis in Type II diabetes (9, 84). The hypothesis to be tested is that
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high lipid levels can cause abnormalities in insulin dependent glucose clearance in 
aortic endothelial cells (EC) and arterial smooth muscle cells (SMC). We further 
hypothesize that the glucose clearance in the presence of high lipid levels will decrease 
from that seen without lipids in both aortic endothelial cells and arterial smooth muscle 
cells, and that there will be a significant difference between the cell types with respect to 
glucose handling. It is expected that the glucose clearance by endothelial cells and 
arterial smooth muscle cells under normal physiologic levels of lipids will remain the 
same as the glucose clearance in the absence of lipids.
1.10 Specific aims
1. To establish an in vitro experimental model to enable detection of 
insulin dependent glucose clearance in aortic endothelial cells and 
arterial smooth muscle cells.
Questions to be answered include:
a) Can glucose clearance be measured in standard cell culture media 
(DMEM)?
b) Does bovine insulin cause measurable increases in insulin-dependent 
glucose clearance in non-bovine cell types?
c) Does glucose starvation enhance insulin-dependent glucose clearance 
in vitrol
d) Are the triglyceride concentrations used for the experiments toxic to 
cells?
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2. To examine glucose clearance under normal glycémie and 
hyperglycemic conditions in glucose-starved (and non-starved) EC and 
SMC.
Questions to be answered include:
a) What is the optimal glucose-starvation time for measurement of 
insulin-dependent glucose clearance in these two cell types?
b) Does the addition of insulin cause increased glucose clearance under 
both normal glycémie and hyperglycemic conditions?
c) Do SMC and EC respond differently to normal glycémie and 
hyperglycemic conditions?
3. To examine the effect of two widely different concentrations of 
triglycerides on glucose clearance by both cell types.
Questions to be answered include:
a) Do normal physiologic triglyceride levels (45 mg/dl) affect insulin- 
dependent glucose clearance for cells under normal and hyperglycemic 
conditions?
b) Do high triglyceride levels (200 mg/dl) affect insulin-dependent 
glucose clearance for cells under normal and hyperglycemic 
conditions?
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1.11 Rationale for the experimental design
Endothelial cells and smooth muscle cells from sheep were chosen because of 
their availability and the acceptability of the sheep as a large animal model for many 
cardiovascular experiments.
Endothelial cells were chosen because of their homeostatic role at the blood 
interface, and their potential influence on lipid accumulation, and atherosclerosis in blood 
vessels (88), and because of the evidence of endothelial dysfunction in diabetes (20), 
Smooth muscle cells were selected because, like the tissue from which they originate, 
they require an adequate blood supply for their function. These cells also play an 
important role in glucose homeostasis and insulin action (26).
In order to compare the effect of hyperglycemia and high triglycerides on two 
different cell types, culturing conditions for both cell types must be normalized. For this 
purpose the cell number in each culture was determined so that all measurements could 
be expressed on a per cell basis. All experiments were also conducted soon after cells 
became confluent using normal medium containing fetal bovine serum. The experiments 
began with the starvation of cells in glucose- and serum-free medium. All subsequent 
glucose or triglycerides supplements were added to the glucose- and serum-free medium, 
so that the concentrations of both added supplements were well defined.
The success of this study depended heavily on the ability to measure changes in 
the glucose clearance from the medium. The detection of glucose clearance from the 
medium was the method of choice because the issue of intracellular breakdown of 
glucose during the experimental period can be avoided. The Sigma GAGO (glucose)
1 8
assay kit was chosen because the glucose oxidase/peroxidase assay system was simpler, 
more accurate and sensitive than an assay employing a straight chemical detection 
method such as the Nelson procedure (82).
It is possible that a high level of triglycerides could be toxic to cells, and this 
could invalidate any negative effects observed. For this purpose, lactate dehydrogenase 
assay (LDH) and Trypan Blue staining were used to assess cell viability prior to the 
termination of the experiments.
In Specific Aim 2, glucose-starvation was used to mimic clinical glucose- 
tolerance testing. A series of experiments were designed to determine the optimum 
starvation period to maximize glucose clearance by SMC and EC under normal glycémie 
and hyperglycemic conditions. The longest starvation period to be tested was cut to 6 hrs 
because some cells, such as the adipocytes, cannot tolerate or survive beyond this period 
(personal communication, V.R. Grund). Because of this, any data obtained from SMC 
and EC starved for longer periods would not be comparable with results from other cells 
in future studies. The normal physiological level of insulin (60 mg/dl) was chosen in 
these experiments. Likewise, normal glycémie (70 mg/dl) and hyperglycemic (300 
mg/dl) levels of glucose (for both humans and sheep) were chosen for their clinical 
relevancy.
For Specific Aim 3, normal physiological (45 mg/dl) and elevated (200 mg/dl) 
concentrations of triglycerides were added to the system described in Specific Aim 2. 
Although the level (200 mg/dl) is considered moderately high, patients with such a level 
of triglycerides may be at the beginning stage of developing cardiovascular disease (88). 
Furthermore, preliminary experiments indicated that higher levels of triglycerides (in
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combination with other fatty acids and lipids) were toxic to cells in vitro. Triglycerides 
were used because they are associated with hyperinsulinemia, abnormal glucose 
tolerance, as well as high levels of LDL, VLDL, and decreased levels of HDL. Cell 
culture conditions again were normalized. Selected and counted cells were grown in the 
presence of triglycerides for 1, 7 and 14 days. Glucose clearance per cell from the culture 
media containing hyperglycemic and normal glycémie initial concentrations of glucose 
was determined. Sterile Intralipid 20% Fat Emulsion from Baxter Healthcare 
Corporation (Deerfield, IL) was used as a source of triglycerides, which are present in 
this emulsion at 200 mg/ml in a mixture with fatty acids such as linoleic (44-62%), oleic 
(19-30%), palmitic (7-14%), linolenic (4-11%), and stearic (1.4-5.5%). Other ingredients 
are Soybean Oil (20%), Egg Yolk Phospholipids (1.2%), Glycerin (2.25%), and water.
2.0 MATERIALS AND METHODS
2.1 Materials and reagents
Dulbecco's Modified Eagle's Medium (DMEM), containing gentamicin and 
fungizone was obtained from GEBCO BRL (Grand Island, NY), and supplemented with 
10% fetal bovine serum (FBS) from Hyclone (Logan,UT). Another GIBCO product, 
RPMI 1640 Glucose-free medium was already prepared by the manufacturer and ready to 
be used for tissue cultures. Bovine insulin (GEBCO) was selected for the availability, 
cost and a high reported cross-reactivity with cells of other species. M l 99 medium also 
from GIBCO BRL was supplemented with 20% FBS, fungizone and gentamicin from the 
same company. Glucose assay kit GAGO-20 containing oxidase-peroxidase reagent and 
p-D-glucose were obtained from SIGMA (St. Louis, MO) and used according to the 
manufacturer’s recommendations. Intralipid 20% fat emulsion was received from Baxter 
Healthcare Corporation (Deerfield, IL). The absorbance values were obtained using a 
Microplate reader UNISKAN11 (McLean, VA). Pyruvate, NADH, and Lactate 
dehydrogenase (LDH) enzyme were obtained from SIGMA (St. LOUIS, MO). The 
absorbance readings for the LDH analysis were performed on a spectrophotometer 
(Thennomax Microplate Reader) at the University of Montana, Department of 
Pharmaceutical Sciences.
2 0
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2.2 Methods
2.2.1 Endothelial cell isolation:
EC were harvested from the descending aorta. The ends of the aorta were kept in 
70% ethanol for 5min to prevent growth of cells other than endothelial, and to make sure 
that our further measurements of glucose clearance would not be positively or negatively 
influenced by a mixture of different cells. The outside surface of the sheep aorta was 
sterilized with 70% ethanol. The EC were captured following trypsinization (1% trypsin) 
and flushed through with medium [M l99 (GIBCO) with 20% FBS, fungizone and 
gentamicin combination]. Endothelial cell growth factor was used to promote cell 
growth. EC were maintained in M l99 medium and incubated at 37°C in a humidified 
enviromuent containing 5% CO2 .
2.2.2 Smooth muscle cell isolation:
Sections of sheep artery were obtained and the outer tissue removed with forceps. The 
pieces were rinsed with FBS free DMEM, and sterilized with 70% ethanol. The margin 
was trimmed off and the remainder was cut into approximately 1mm pieces. The pieces 
were placed in a 50 ml centrifuge tube with 6 ml of collagenase (0.1%) in PBS and 
incubated for Ihr at 37°C. Following the incubation, the supernatant was removed and 
10 ml of DMEM media with 10% FBS was added. The mixture was centrifuged at 1600 
RPM for 5 min. Following centrifugation, the supernatant was removed and DMEM 
media with 10% FBS was added to the total volume of 20 ml, which was split into two 
plates. Cells were grown at 37°C in a humidified atmosphere containing 5% CO2
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2.2.3 Modified glucose assay for microtiter plate using GAGO-20 Glucose Assay 
Kit:
Stock glucose standards stored at 4^C were made using directions in Table 1.
Table 1. Glucose Standards
Tube Volume of Glucose 
Free Media in pi
Volume of Glucose 
Standard Solution 
(1 mg/ml) in pi
Concentration of 
Glucose in mg/ml
Blank 1000 0 0
Standard # 1 980 20 0.02
Standard #2 960 40 0.04
Standard #3 940 60 0.06
Standard #4 920 80 0.08
Standards and samples vortexed to homogeneity, were added in the volume of 
50 pi into microtiter wells and diluted to be in the range of the standard curve 
0.02-0.08 mg/ml. Glucose-peroxidase assay reagent (100 pi) was pipeted into wells 
every 30 sec. The enzymatic reaction was stopped by the addition of 100 pi of 12N 
H2 SO4 , to the total volume of 250 pi, following the incubation for 30 min at 37°C in a dry 
incubator with 5% CO2. Following this addition, samples were again kept in the same 
incubator under the same conditions for another 30 min to assure uniform color 
distribution in the wells. Absorbances were then determined with a microplate reader at 
492 nm. Data were used to create a calibration curve where the X axis contained 
concentrations in mg/ml and the Y axis represented optical density. Regression analysis 
was used on every linear standard curve to determine the equation for the best fit line 
from which the sample concentrations were obtained.
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2.2.4 Baseline glucose clearance:
Smooth muscle or endothelial cells were starved for 0, 2, 4 and 6 hrs in glucose 
free RPMI 1640 or fed by DMEM media with 10% FBS, and were rinsed twice prior to 
analysis with fresh glucose free media. Following the rinse, 10 ml of the same fresh 
media was added into each plate. When studying normal glycémie levels of glucose, 
both plates received 70 pi of glucose from 100 mg/ml stock, giving a final concentration 
of 70 mg/dl. This would actually correspond to normal fasting plasma glucose levels.
For hyperglycemic levels, plates received 300 pi of glucose (100 mg/ml), giving a final 
concentration of 300 mg/dl. Samples were pipetted in duplicate from each plate in the 
volume of 130 pi. This sample served to measure glucose clearance at 0 min. Following 
this first sampling, one of the two plates received 300 pi of bovine insulin 
(20 mg/ml from stock). The normal physiologic concentration of insulin is 60-150 mg/dl. 
After the addition of insulin, samples of 130 pi were obtained in 5, 10, 15, 20, 40, 60, 90, 
120 min and 24 hrs from both plates in duplicate. These samples were diluted, treated, 
assayed, and concentrations were obtained by the modified glucose assay protocol for the 
microplate reader. Sample concentrations were graphed as a function of time for each 
cell type.
Modifications in later experiments were made so that experiments could be done 
in 24-well tissue culture plates (Falcon).
2.2.5 Cell counting:
Medium used to feed EC and SMC was removed from plates. Plates were rinsed 
with FBS free DMEM. Cells were trypsinized and DMEM medium with 5% FBS was
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added to the plates. Trypsinized cells in the mixture with DMEM medium were placed in 
centrifuge tubes and centrifuged at 2,400 RPM (Beckman, OPR Centrifuge). Following 
the centrifugation, supernatant was removed and 3ml of DMEM media free of FBS was 
added. The cell mixture was vortexed and lOpl was added to a hemocytometer. The 
total number of cells was obtained by counting under the microscope. Viability was 
determined by Trypan blue exclusion.
2.2.6 Lactate dehydrogenase analysis:
An LDH protocol, modified by the University of Montana, Department of 
Pharmaceutical Sciences, was used to measure the LDH reaction. This reaction follows 
conversion of glucose to pyruvate, and serves to regenerate NAD"  ̂from NADH. KH2PO4 
(13.6 g) was dissolved in IL nanopure water to generate a O.IM solution (pH 7.2) and 
100 pi was mixed with 123 mg of pyruvate. This pyruvate assay solution was stored at 
4°C. LDH enzyme (2 pi) was diluted in 4,000 pi 0.1 M KH2PO4. An NADH solution 
was prepared just prior to assay to prevent formation of potent enzyme inhibitors, which 
can form in frozen solution or damp powder. NADH (13 mg) was dissolved in 10 ml 0.1 
M KH2PO4.
Pyruvate solution (50 pi) was added to all wells except the top left well, which 
was left as a blank. Standards were mixed in the following order and added to wells 
(Table 2):
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Table 2. LDH Standard Curve
Units LDH (pi) KH2PO4 (pi)
0 0 50
0.002 2 48
0.005 5 45
0.01 10 40
0.015 15 35
0.02 20 30
0.03 30 20
0 04 40 10
0.05 50 0
In the next step 50 pi KH2PO4 was added to create a total volume of 150 pi. All 
samples were pipetted into additional wells in the volume of 100 pi. The total volume of 
samples and pyruvate was 150 pi. Parameters on the plate reader were set up and 50 pi 
NADH was rapidly added to all wells. Absorbance values at 492 nm (Spectrophotometer 
Thermomax Microplate Reader) were obtained immediately following the addition of 
NADH. For a positive control value, the cells from each sample were lysed in Triton-X 
100, and cell lysates were assayed for LDH as above. Values for LDH in u were 
compared to this total cellular LDH and expressed as a percent of positive control.
2.2.7 Glucose clearance in the presence of triglycerides:
SMC and EC were kept in the presence of normal physiologic concentrations of 
triglycerides (45 mg/dl) or above normal triglyceride concentrations (200 mg/dl) for 1, 7 
and 14 days. Intralipid 20% fat emulsion was used as a source of triglycerides present in 
this lipid emulsion in the concentration 200 mg/ml. Other major components in this lipid 
emulsion were fatty acids such as linoleic (44-62%), oleic (10-30%), palmitic (7-14%), 
linolenic (4-11%) and stearic (1.4-5.5%). The sterile lipid emulsion was stored at 4®C.
26
Studies were performed to demonstrate a consistent baseline glucose clearance in 
each cell type to which these obtained values were compared. When experiments were 
modified for 6 and 24-well plates, differences in volume and cell number were taken into 
account. Glucose clearance was measured for each cell type with 70 mg/dl and 300 
mg/dl glucose exposure, with or without the presence of insulin, after 1, 7 and 14 days of 
incubation with the lipid emulsion as described in the modified glucose assay. Dilutions 
for the initial glucose concentrations of 70 mg/dl (1:10) and 300 mg/dl (1:50) were made 
to fit the calibration curve between 0.02-0.08 mg/ml.
3.0 STATISTICAL ANALYSIS
Several comparisons were made on the glucose clearance data obtained in this 
study. The two major effects analyzed statistically were, a) a statistically significant 
increase in glucose clearance when insulin was added to the culture, and b) differences in 
glucose clearance between the responses by the two cell types. Some experiments were 
performed with duplicate aliquots from single samples, which provided information 
regarding the reproducibility of the assay. Subsequently, triplicate (or more) samples 
were included in the statistical analyses where shown, using multiple concentrations as 
the variable treatments. Statistical variance (P) among treatment sets was determined by 
the One Way ANOVA test using Minitab Statistic Program. Statistically significant 
results were defined as p < 0.05.
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4.0 RESULTS
4.1 To establish an in vitro experimental model to enable detection of insulin-
dependent glucose clearance in aortic endothelial and arterial smooth muscle 
cells.
The initial experiments were conducted to measure glucose clearance by rabbit 
skeletal muscle cells and human fibroblasts in basic cell culture media. The amount of 
glucose present in the standard (DMEM) media (450 mg/dl) was too high, and therefore 
any change in glucose clearance by cells could not be accurately measured. Therefore, 
glucose-free medium with specific amounts of glucose added was used for subsequent 
measurements, and glucose concentrations in the media were measured at 0, 20, 60, 120, 
240, 360 min, and 24 hr. Using the combination of this culture system and the GAGO 
glucose assay method, an approximately 10% insulin-dependent glucose clearance was 
observed after 24 hrs when an initial hyperglycemic level of glucose (300 mg/dl) was 
present (data not shown).
A significantly higher reduction of glucose from supplemented glucose-free 
medium was observed when insulin was used as compared to the baseline glucose 
clearance in the absence of insulin (data not shown, see later experiments). This 
confirmed that the culture conditions and the assay method were adequate to measure 
bovine insulin-dependent glucose clearance by both cell types.
Preliminary results also showed that glucose starvation for 4 hrs significantly 
increased the difference (30-60%) in glucose clearance seen with and without insulin by 
rabbit skeletal muscle cells, sheep corneal endothelial cells, and human fibroblasts.
2 8
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All subsequent experiments were done using EC and smooth muscle cells SMC 
from sheep arteries. Cells were characterized by staining, using 
a-actin stain to identity SMC and von Willebrand Factor to identify EC. Cells were 
grown to confluence and photographed at 4 Ox magnification for morphological 
appearance (Fig. 1 and 2).
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Fig.l. SMC from sheep at 40X magnification.
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Fig.2. EC from sheep at 40X magnification.
A commercial preparation of triglycerides was used in this study. In order to 
ensure that this triglyceride preparation was not toxic to cells, LDH in the tissue culture 
media was measured as an indicator of cell death. LDH concentrations in the media of 
EC cultures remained below 10% of total cellular LDH for all concentrations of 
triglycerides used, with and without insulin (Fig. 3 A). Similar results were obtained for 
SMC (Fig. 3B). Trypan blue staining also showed viability of cells remained above 90% 
throughout subsequent experiments.
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Fig. 3A. LDH analysis for EC. Values represents [LDH] averaged percentages of 
positive control (total cellular LDH) for EC obtained over 14 days from tissue culture 
containing 1 mg/dl, 10 mg/dl or 100 mg/dl triglycerides. Error = s.d., n = 14.
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Fig 3B. LDH analysis for SMC. Values represents [LDH] averaged percentages of 
positive control (total cellular LDH) for SMC obtained over 14 days from tissue culture 
containing 1 mg/dl, 10 mg/dl or 100 mg/dl triglycerides. Error = s.d., n = 14.
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4.2 To examine glucose clearance under normal glvcemic and hyperglycemic
conditions in glucose-starved (and non-starved) EC and SMC (Specific Aim 2).
The effect of baseline insulin treatment under selected glucose starvation times (0, 
2, 4, and 6 hr) was established to make sure that the period selected provided efficient 
insulin-dependent glucose clearance by EC and SMC. Another reason to evaluate the 
basal insulin treatment effect was the possibility that insulin resistance would be observed 
during our experiments in the presence of elevated triglycerides.
Insulin treatment caused increases in glucose clearance under most conditions. 
However, at the higher glucose concentration, insulin had little effect at 0 and 2 hr 
starvation for either cell type (Fig. 4A and B). The insulin treatment caused a significant 
increase in glucose clearance, and the glucose clearance/cell in the presence of insulin 
had the largest value for EC with an initial glucose concentration of 300 mg/dl following 
the 4hr starvation time (Fig. 4A). The insulin treatment for SMC with an initial glucose 
concentration of 300 mg/dl was significant for a 4hr starvation period (Fig. 4B). 
Therefore, the 4 hr glucose starvation period was used for subsequent experiments.
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Figure 4A. Effect of glucose starvation on EC. EC were starved in glucose-free 
medium for the indicated times. The total glucose clearance/cell for 70 mg/dl and 300 
mg/dl initial glucose concentration with and without insulin was measured. Values are 
averages of duplicate aliquots of single samples with error = range, except at the 4hr 
points where n=4, error bar = s.d., and * = p<0.05
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Figure 4B. Effect of glucose-starvation on SMC. SMC were starved for indicated 
times. The total glucose clearance/cell for 70 mg/dl and 300 mg/dl initial glucose 
concentration with and without insulin was measured. Values represent averages of 
duplicate aliquots of single samples with error = range, except at the 4 hr points where 
n=4, error bar = s.d., and * = p<0.05.
The difference in glucose clearance between EC and SMC following glucose 
starvation was evaluated at a normal glycémie glucose concentration (70 mg/dl) (Fig 5A) 
and hyperglycemic glucose concentration (300 mg/dl) (Fig. 5B). Under most conditions 
EC took up slightly more glucose than SMC. The patterns of glucose clearance over the 
various starvation times varied between the cells, with glucose starvation time having a 
more dramatic effect on the SMC. This suggests that glucose clearance is regulated 
differently in the two cell types. Increasing the glucose concentration led to increased 
clearance with or without insulin in EC and SMC, but this increase was more pronounced 
for the SMC so that differences between the cell types diminished at the higher glucose 
concentration. For example, at 70 mg/dl glucose, at the 4 hr glucose starvation time point
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the difference between the two cell types was statistically significant with and without 
insulin (Fig 5A), but there was no significant difference between the cells at 300 mg/dl.
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Figure 5.A. EC and SMC were glucose starved for indicated times. The total glucose 
clearance/cell for 70 mg/dl initial glucose concentration with or without insulin was 
performed. Values represent averages of duplicate aliquots of single samples with error 
= range, except at 4 hr points where n=4, error bar = s.d., and * = p<0.05.
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Figure 5.B. EC and SMC were glucose starved for indicated times. The total glucose 
clearance/cell for 300 mg/dl initial glucose concentration with or without insulin was 
measured. Values represent averages of duplicate aliquots of single samples with error 
range, except at 4 hr points were n = 4, error bar = s.d., and * = p<0.05.
4.3 To examine the effect of two widelv different concentrations of triglvcerides
on glucose clearance bv both cell tvnes (Specific Aim 3).
The last set of experiments evaluated glucose clearance by EC and SMC in the 
presence of normal physiologic plasma triglyceride concentrations (45 mg/dl), or slightly 
elevated plasma triglyceride concentrations (200 mg/dl). Graphical representations of the 
results are shown in Figures 6-9. The obtained measurements were also compared with 
appropriate baselines (glucose clearance in the absence of lipids) which have been shown 
to be consistent through repeated experiments. Calculated (Table 1-2), and graphical 
representations of differences from baselines were made, and can be found in Figure 10- 
17.
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In the presence of normal physiologic concentrations of TGC (45 mg/dl) and 
glucose (70 mg/dl), the insulin treatment caused a significant increase in glucose 
clearance by both cell types. Interestingly, the glucose clearance by EC and arterial 
smooth muscle cells calculated per cell, in the absence or presence of insulin increased as 
compared with baselines after 1 day in TGC (Fig. 6,10,11). The glucose clearance further 
increased following the 7^ day of incubation with TGC. After 14 days, the glucose 
clearance by both types of cells dropped, and reached values closer to baselines (Fig. 10 
and 11). EC and SMC responded very similarly. This opposes the hypothesis that the 
glucose clearance by both cell types would remain the same as the baseline (Fig. 6A-B).
Similar results were seen for EC even when glucose was elevated to 
hyperglycemic levels (Fig. 7A). There was an increase in glucose clearance by EC during 
the 14 days of experimentation as compared with baseline in the presence or absence of 
insulin (Fig. 12,13). However, in contrast to EC, the glucose clearance by SMC was not 
enhanced above baselines by the triglycerides at this concentration of glucose (Fig. 12).
With higher concentrations of triglycerides (200 mg/dl), and normal glycémie 
plasma glucose concentration 70 mg/dl, insulin treatment caused a significant increase in 
glucose clearance by EC on theT^ and 14* day of the experiments, while by SMC this 
significant increase in glucose clearance was seen on the and 7* day of the 
experiments (Fig. 8A-B). In the absence of insulin, the glucose clearance by EC dropped 
during the 14 days of experimentation from well above the baseline to below it (Fig. 14). 
The same trend of decrease was seen in SMC during the 14 days of the experiment, but 
unlike the EC, there was not an initial increase above the baseline (Fig. 14, 15).
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In the absence of insulin, the glucose clearance by both SMC and EC dropped 
below the baseline (Fig. 16). However, SMC remained sensitive to insulin whereas 
glucose clearance by EC was no longer significantly enhanced by the addition of insulin 
(Fig. 9A-B). Therefore, in these conditions both cells behaved similarly in the presence 
or absence of insulin except for the loss of sensitivity to insulin by EC (Fig. 16 and 17). 
These conditions also induced morphological changes in the SMC, including rounding up 
and loss of adherence, that were not seen in the absence of lipids (Fig. 1 and 18). These 
morphological changes were not observed in EC.
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Fig. 6A. Effect of normal physiologic concentrations of triglycerides (45 mg/dl) on 
glucose clearance by EC at normal glycémie concentration (70 mg/dl). The averaged 
baseline uptake in the absence of insulin was 7.14 pg/dl/cell, and in the presence of 
insulin 12.88 pg/dl/cell. Error = s.d., n=4,* = p<0.05
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Fig. 6B. Effect of normal physiologic concentrations of triglycerides (45 mg/dl) on 
glucose clearance by SMC at normal glycémie concentration (70 mg/dl). The averaged 
baseline uptake in the absence of insulin was 4.02 pg/dl/cell, and in the presence of 
insulin 9.65 pg/dl/cell. Error = s.d., n=4, * = p<0.05
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Fig. 7A. Effect of normal physiologic concentrations of triglycerides (45 mg/dl) on 
glucose clearance by EC at hyperglycemic concentration (300 mg/dl). The averaged 
baseline uptake in the absence of insulin was 20.16 pg/dl/cell, and in the presence of 
insulin 31.18 pg/dl/cell Error = s.d., n=4.* = p<0.05
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Fig. 7B. Effect of normal physiologic concentrations of triglycerides (45 mg/dl) on 
glucose clearance by SMC at hyperglycemic concentration (300 mg/dl). The baseline 
uptake in the absence of insulin was 18.93 pg/dl/cell, and in the presence of insulin 22.83 
pg/dl/cell. Error = s.d., n=4, * = p<0.05
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Fig. 8A. Effect of elevated concentrations of triglycerides (200 mg/dl) on glucose 
clearance by EC at monnal glycémie glucose concentration (70 mg/dl). The averaged 
baseline uptake in the absence of insulin was 7.14 pg/dl/cell, and in the presence of 
insulin 12.88 pg/dl/cell. Error = s.d., n=4,
* = p<0.05
16 
Ë 14
IS  12
% 10
6 -
j t— ► a ’
b c
□  1 Day in TGC 
17 Days in TGC 
114 Days in TGC
No Insulin insulin
Fig. 8B. Effect of elevated concentrations of triglycerides (200 mg/dl) on glucose 
clearance by SMC at normal glycémie glucose concentration (70 mg/dl). The averaged 
baseline uptake in the absence of insulin was 4.02 pg/dl/cell, and in the presence of 
insulin 9.65 pg/dl/cell. Error = s.d., n=4, * = p<0.05
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Fig. 9A. Effect of elevated concentrations of triglycerides (200 mg/dl) on glucose 
clearance by EC at hyperglycemic glucose concentration 300 mg/dl. The averaged 
baseline uptake in the absence of insulin was 20.16 pg/dl/cell, and in the presence of 
insulin 31.18 pg/dl/cell. Error = s.d., n=4, *= p<0.05
o 10
□  1 Day In TGC 
17 Days In TGC 
114 Days In TGC
No Insulin Insulin
Fig. 9B. Effect of elevated concentrations of triglycerides (200 mg/dl) on glucose 
clearance by SMC at hyperglycemic glucose concentration (300 mg/dl). The averaged 
baseline uptake in the absence of insulin was 18.93 pg/dl/cell, and in the presence of 
insulin 22.83 pg/dl/cell. Error = s.d., n=4, * = p<0.05
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Table 1. Averaged values (n=4) of glucose clearance by EC and SMC taken as a 
differences from appropriate average baselines for both cell types following incubation in 
45 mg/dl TGC, initial glucose concentration 70 mg/dl and 300 mg/dl, absence and 
presence of insulin.
Cell Type Initial
Glucose
Cone.
Insulin
(Y/N)
Glucose 
clearance 
after day 
in TGC 
(pg/dl/cell)
Glucose 
clearance 
after 7^ day 
in TGC 
(pg/dl/cell)
Glucose 
clearance 
after 14^ 
day in TGC 
(pg/dl/cell)
EC 70 mg/dl N 11.86 34.86 20.36
SMC 70 mg/dl N 5.0 9.0 7.0
EC 300 mg/dl N 10.84 31.84 26.84
SMC 300 mg/dl N -4.93 -1.93 -0.93
EC 70 mg/dl Y 19.62 44.62 19.62
SMC 70 mg/dl Y 1.35 12.85 8.35
EC 300 mg/dl Y 18.82 50.82 21.82
SMC 300 mg/dl Y -8.83 21.17 4.67
Table 2. Averaged values (n=4) of glucose clearance by EC and SMC taken as a 
differences from appropriate average baselines for both cell types following incubation in 
200 mg/dl TGC, initial glucose concentration 70 mg/dl and 300 mg/dl, absence and 
presence of insulin.
Cell Type Initial
Glucose
Cone.
Insulin
(Y/N)
Glucose 
clearance 
after Î  ̂day 
in TGC 
(pg/dl/cell)
Glucose 
clearance 
after 7^ day 
in TGC 
(pg/dl/cell)
Glucose 
clearance 
after 14* 
day in TGC 
(pg/dl/cell)
EC 70 mg/dl N 7.86 2.86 -4.64
SMC 70 mg/dl N -0.35 -2.22 -2.23
EC 300 mg/dl N 21.84 11.84 -3.16
SMC 300 mg/dl N -0.93 -3.93 -15.93
EC 70 mg/dl Y 27.12 0.12 10.12
SMC 70 mg/dl Y 4.35 -2.65 -7.85
EC 300 mg/dl Y 21.82 0.82 0
SMC 300 mg/dl Y 1.17 14.17 -18.83
CD
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Fig. 10 Glucose clearances by EC and SMC taken as differences from appropriate 
baselines obtained for both cells following 4hr starvation and no triglycerides present. 
* = p<0.05, n=4, s.d. shown in figures 6-9. The maximum change from the baseline is 
5.8 fold (EC) and 3.2 fold (SMC), obtained by dividing highest or lowest value by the 
baseline.
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Fig. 11 Glucose clearances by EC and SMC taken as differences from appropriate 
baselines obtained for both cells following 4hr starvation and no triglycerides present.
* = p<0.05, n=4, s.d. shown in figures 6-9. The maximum change from the baseline is 
4.5 fold (EC) and 2.3 fold (SMC).
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SAEC and  SASMC, with 45mg/dl TGC, 300mg/dl Initial g lu co se  concentra tion , and no
insulin
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Fig. 12 Glucose clearances by EC and SMC taken as differences from appropriate 
baselines obtained for both cells following 4hr starvation and no triglycerides present. 
* = p<0.05, n=4, s.d. shown in figures 6-9. The maximum change from the baseline is 
2.57 fold (EC) and 0.92 fold (SMC).
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Fig. 13 Glucose clearances by EC and SMC taken as differences from appropriate 
baselines obtained for both cells following 4hr starvation and no triglycerides present. 
* = p<0.05, n=4, s.d. shown in figures 6-9. The maximum change from the baseline is 
2.73 fold (EC) and 1.86 fold (SMC).
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Fig. 14 Glucose clearances by EC and SMC taken as differences from appropriate 
baselines obtained for both cells following 4hr starvation and no triglycerides present. 
* = p<0.05, n=4, s.d. shown in figures 6-9. The maximum change from the baseline is 
2.1 fold (EC) and 0.37 fold (SMC).
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Fig. 15 Glucose clearances by EC and SMC taken as differences from appropriate 
baselines obtained for both cells following 4hr starvation and no triglycerides present. 
* = p<0.05, n=4, s.d. shown in figures 6-9. The maximum change from the baseline is 
3.26 fold (EC) and 0.19 fold (SMC).
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Fig. 16 Glucose clearances by EC and SMC taken as differences from appropriate 
baselines obtained for both cells following 4hr starvation and no triglycerides present. 
* = p<0.05, n=4, s.d. shown in figures 6-9. The maximum change from the baseline is 
2.1 fold (EC) and 0.13 fold (SMC).
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Fig. 17 Glucose clearances by EC and SMC taken as differences from appropriate 
baselines obtained for both cells following 4hr starvation and no triglycerides present. 
* = p<0.05, n=4, s.d. shown in figures 6-9. The maximum change from the baseline is 
1.82 fold (EC) and 0.13 fold (SMC).
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Fig.18. SMC from sheep following 5 day incubation in 200 mg/dl triglycerides, 40X 
magnification.
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5.0 DISCUSSION
Diabetes is a serious endocrine and metabolic disease presenting with elevated 
glucose levels (hyperglycemia), and increased plasma levels of amino acids and lipids. 
Other important factors presently in the center of diabetic research are hyperinsulinemia 
and hypertriglyceridemia (9,16,53,97). There are many in vivo studies evaluating the 
relationships between hyperglycemia, hypertriglyceridemia and hyperinsulinemia. 
However the roles of these factors in in vitro models still needs to be explored.
In the present study, the effects of hypertriglyceridemia in an in vitro model using 
EC and SMC were evaluated. Two cell types were selected because the preliminary 
studies of glucose clearance from the medium by distinct cell types suggested that they 
have apparent differences in glucose utilization and metabolism in vitro. This 
corresponds to published information on the highly variable kinetics of specific glucose 
transporters expressed on different cell types (2,3,14,86). The main transporters in 
muscle and endothelial cells are GLUT 4 and GLUT 1, respectively (19,54,116,131). 
GLUT 4 transports glucose faster and it has a higher affinity for glucose than GLUT 1 
(22,89).
Two initial glucose concentrations were selected. One was near normal (fasting) 
glycémie levels in sheep as well as in human (70 mg/dl), and the other was a 
hyperglycemic concentration (300 mg/dl). Higher concentrations were not used because 
the preliminary studies showed that the sensitivity of detecting the clearance of these high 
glucose concentrations diminished (Data not shown).
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Triglycerides were also added in two different concentrations. One was a normal 
plasma triglyceride concentration (45 mg/dl), and the other was a slightly elevated 
plasma triglyceride concentration (200 mg/dl). Higher triglyceride concentrations were 
not selected because preliminary studies suggested that concentrations higher than 200 
mg/dl were toxic to cells.
Preliminary studies also suggested that glucose starvation resulted in differences 
between insulin-dependent and non-insulin-dependent glucose clearance by different 
cells. With the different glucose starvation times selected (2, 4, and 6 hi), a statistically 
significant optimal period was not obtained. Instead, the 4-hr starvation time was chosen 
for subsequent experiments based on trends seen at high concentrations of glucose where 
starvation appeared to enhance the effect of insulin. The starvation time was intended to 
mimic clinical glucose tolerance tests, with the idea of maximizing intracellular glucose 
depletion and minimizing glucose transporter expression at the cell surface. In this way, 
glucose clearance upon addition of glucose would be driven by the glucose gradient, and 
the effect of insulin would be seen as additional glucose transporters were expressed on 
the cell surfaces in response to insulin binding.
Glucose clearance by EC (expressed on a per cell basis throughout this study) was 
greater than by SMC suggesting that these cell types may have different glucose 
requirements. This could be perhaps due to the earlier described differences in GLUT 1 
and GLUT 4 transporters and their distinct affinity for glucose (22,89). Differences 
between the cell types diminished at the higher glucose concentration, and this may 
simply be a reflection of the dynamics of the particular glucose transporters expressed on 
these cells. However, it does suggest that the two cell types responded differently to the
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increase. Insulin caused significant increases in glucose clearance in both cell types at 
both normal glycémie and hyperglycemic glucose concentrations.
The next set of experiments addressed the question of how the glucose clearance 
by EC and SMC is influenced by triglycerides. In the presence of a normal glycémie 
glucose concentration, addition of triglycerides at a physiologic level led to an increase in 
non-insulin dependent glucose clearance by both cell types. This increase was further 
affected by insulin (Fig.6A-B). This enhancement effect of triglycerides could be due to 
£in adjustment of the cells to the environment or to some other function of the lipids that 
affected glucose clearance. The lipids used in the study contained mixture of fatty acids. 
It was observed in vivo that addition of fatty acids lead to increased glucose utilization 
(132,133). However, at a high concentration of glucose, the normal level of triglycerides 
did not increase the non-insulin-dependent glucose clearance by SMC above the baseline 
level (Fig. 12). Similarly, after 1 day of incubation in a physiologic concentration of 
triglycerides, the increase of insulin-dependent glucose clearance by SMC was lost in the 
presence of hyperglycemic level of glucose (Fig 7B). SMC therefore appeared to be 
more sensitive to the increase in glucose concentration. This phenomenon is probably 
due to the presence of GLUT 4 transporters in smooth muscle cells that is responsible for 
higher affinity for glucose than GLUT 1 transporter (22,89).
When an elevated triglyceride level (200 mg/dl) was used in combination with a 
normal glycémie level of glucose, the non-insulin-dependent glucose clearance was no 
longer enhanced in either cell type (Fig. 8A and 8B). Also, the insulin effect was no 
longer significant for EC at day 7 (Fig.SA). This is consistent with what is observed in 
hypertriglyceridemia related insulin resistance in vivo (8,12,16,51,120), in which high
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levels of triglycerides reduce cellular responses to insulin. Under the same conditions, 
although the insulin-dependent glucose clearance by SMC increased significantly on day
I and 7, the glucose clearance dropped dramatically by day 14 (Fig.SB).
The most intriguing results were obtained when an elevated concentration of 
triglycerides was used in combination with hyperglycemic plasma glucose concentration 
(Fig.9A and B). Without insulin, both cell types showed the same pattern of 
progressively decreasing glucose clearance over the 14 days. Therefore, the main 
difference between the cell types under these conditions occurred in the presence of 
insulin, where SMC showed more insulin sensitivity than EC for the first 7 days. Data 
for day 14 was inconclusive for comparison between the cell types due to a loss of 
adherence by the SMC. The patterns of sensitivity differed between the cell types 
depending on triglyceride and glucose concentrations, but the EC clearly showed insulin 
insensitivity when both glucose and triglycerides were high. The important issue in Type
II Diabetes Mellitus is the relationship between hyperglycemia, hypertriglyceridemia and 
insulin resistance. It has not been conclusively shown which of these three factors lead to 
the other two. The current study suggests that high triglyceride levels lead to insulin 
resistance in endothelial cells perhaps due to dysfunction of vascular endothelium that 
has been observed in diabetic patients (20). Interestingly, both concentrations of lipids 
enhanced overall glucose clearance above that seen without lipids only in the endothelial 
cells, whereas in SMC, this effect of lipids was only seen at the lower concentrations of 
both lipids and glucose.
The possibility exists that decreased glucose clearance by SMC was due to 
toxicity of triglycerides. It is important not to overlook the fact that the triglycerides that
were used in our model were in combination with fatty acids and other ingredients. These 
ingredients in the lipid emulsion could be responsible for cell toxicity; however, this 
does not seem to be the case since viability studies using Trypan blue suggested that the 
cells remained 90-95% viable. For future studies, it would be ideal if triglycerides 
without other ingredients could be used. There is, however, a difficulty in emulsifying 
triglycerides. Perhaps a liposome delivery system should be considered. Another 
possibility is to use plasma from patients with high triglyceride levels, which might 
require the use of human cells instead of sheep cells. Another explanation for some of 
the observed decrease in glucose clearance might have been a loss of adherence by SMC. 
Since they had to be nutritionally supplemented, changing of media depleated the number 
of cells and it was difficult to get accurate counts. Nevertheless, the loss of adherence by 
SMC suggests that the lipids strongly affected these cells, although not in the same way 
as the EC since they remained sensitive to insulin.
In in vivo systems EC cover the smooth muscle cells in vessels. These cells are 
exposed to constantly changing concentrations of chemicals, nutrients, and other 
important elements in the plasma. EC perhaps need to be able to adjust to rapidly 
changing insulin and glucose concentrations in the environment. On the other hand,
SMC could be naïve to similar conditions. In in vitro experiments, our observations of 
SMC becoming intolerant may be due to the fact that these cells are no longer protected 
and perhaps they caimot adjust rapidly to the changes. Although the SMC were affected 
by high levels of lipids in terms of adherence, the EC's showed more insulin insensitivity. 
This insensitivity seen in EC may be a protective mechanism from changing 
environmental conditions that is lacking in SMC.
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The in vitro model used to measure glucose clearance did not evaluate long term 
effects of lipids. Perhaps long term presence of abnormally high triglyceride levels 
would cause dysfunction of EC, and this would increase the possibility of contact of 
naïve SMC with the chemically changing environment. Such an insult could perhaps 
lead to disease and rupturing of vessels. This is commonly seen in diabetic patients. 
Triglyceride concentration of 500 mg/dl could cause irreversible changes in EC and SMC 
already after a short time, and lead to a similar result of vessel damage.
It would be ideal to perform assays in the future using higher insulin 
concentrations. If these phenomena occurred or were alleviated in the presence of higher 
than normal plasma insulin concentration, it would suggest clues to insulin resistance in 
these conditions. This would give us a better understanding of the correlation between 
hyperlipidemia, and hyperglyceridemia and their effect on cardiovascular complications 
in patients with NIDDM (9,75,77). It is important to realize that this system was very 
simplified. It deliberately eliminated the effects of other factors including hormones 
(growth hormone, glucagon, cortisol,...) and other important components influencing 
glucose clearance in vivo as well as influencing regulation of insulin secretion and 
resistance. These eliminated players should be considered for similar evaluation in the 
future for a better understanding of pathological basis of diabetes.
Complex models evaluating the effects of insulin, other hormones, enzymes, such 
as lipoprotein lipase, or combinations of these should be examined in the future. In order 
to evaluate the possibility of insulin resistance in the presence of triglycerides, different 
concentrations of insulin should be used. Much work needs to be done to understand the 
role of triglycerides on the function of glucose transporters corresponding to each cell
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type. More research must also be done to evaluate the significance of lipids in signaling 
pathways that may influence the action of insulin.
Future studies using Syndrome X animals in our model should be considered.
The Syndrome X is presented with genetic hyperlipidemia, angina-like chest pain with a 
normal coronary arteriogram and positive exercise test. The individuals with Syndrome 
X are predisposed to Diabetes Mellitus and suffer from hypertension as well (9,26). In 
order to explore these complex interactions, cell types other than smooth muscle cells and 
endothelial cells should be examined. Good candidates would be hepatocytes, fibroblasts 
and adipocytes.
Careful interpretation of such in vitro data is important to understand the normal 
and Type II diabetic in vivo systems. Future development of a human model instead of 
the sheep model should be considered because of the difficulties of interpretation of 
results between the two species.
6.0 CONCLUSION
In conclusion, high triglyceride levels caused abnonnalities in insulin-dependent 
glucose clearance in sheep aortic endothelial and arterial smooth muscle cells.
Conditions mimicking hyperglycemia and hyperlipidemia induced a response from EC 
that resembled insulin resistance. These conditions also caused a loss of adherence by 
SMC that may have masked other significant effects. The patterns of glucose clearance 
in the presence of 45 mg/dl triglycerides were very similar for both cell types except 
when hyperglycemic glucose concentrations were used. As hypothesized, high lipid 
levels reduced overall glucose clearance compared to clearances seen at physiologic lipid 
levels. Interestingly, physiologic levels of lipids caused an enhancement of glucose 
clearance in both cell types that was not predicted in our stated hypothesis.
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